Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.

ABSTRACT:

Background

Nearly 50% of breast cancer patients suffer from depression or anxiety. Selective serotonin reuptake inhibitors (SSRIs), the first-line pharmacological treatment for depression, have been implicated in breast cancer development through increased prolactin levels and tamoxifen metabolism inhibition. Previous studies of breast cancer progression have focused on tamoxifen users, or have been limited by their small sample size and methodology. Therefore, we used UK population-based data to more robustly investigate the association between SSRI use and cancer-specific mortality.

Methods

A cohort of patients with newly-diagnosed breast cancer between 1998 and 2012 was selected from English cancer registries and linked to prescription records from the Clinical Practice R

SUBMITTER: Busby J 

PROVIDER: S-EPMC5775583 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature